Prelude Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-18,378
| Closed | -$95K | – | 2285 |
|
|
2019
Q2 | $95K | Buy |
18,378
+16,173
| +733% | +$72.7K | ﹤0.01% | 963 |
|
|
2019
Q1 | $8K | Sell |
2,205
-440
| -17% | -$1.91K | ﹤0.01% | 1573 |
|
|
2018
Q4 | $16K | Buy |
2,645
+491
| +23% | +$3K | ﹤0.01% | 1287 |
|
|
2018
Q3 | $13K | Sell |
2,154
-484
| -18% | -$2.42K | ﹤0.01% | 1415 |
|
|
2018
Q2 | $11K | Buy |
2,638
+448
| +20% | +$2.26K | ﹤0.01% | 1480 |
|
|
2018
Q1 | $10K | Buy |
2,190
+1,140
| +109% | +$5.09K | ﹤0.01% | 1360 |
|
|
2017
Q4 | $6K | Buy |
+1,050
| New | +$6.42K | ﹤0.01% | 1257 |
|
|
2016
Q4 | – | Sell |
-1,800
| Closed | -$17K | – | 1915 |
|
|
2016
Q3 | $17K | Buy |
+1,800
| New | +$14.9K | ﹤0.01% | 1367 |
|
|
2016
Q1 | – | Sell |
-21,177
| Closed | -$118K | – | 1662 |
|
|
2015
Q4 | $118K | Sell |
21,177
-11,397
| -35% | -$75.3K | 0.02% | 757 |
|
|
2015
Q3 | $276K | Buy |
32,574
+21,374
| +191% | +$362K | 0.04% | 466 |
|
|
2015
Q2 | $169K | Buy |
11,200
+2,900
| +35% | +$41.9K | 0.02% | 695 |
|
|
2015
Q1 | $133K | Buy |
8,300
+300
| +4% | +$5.34K | 0.02% | 872 |
|
|
2014
Q4 | $143K | Hold |
8,000
| – | – | 0.02% | 859 |
|
|
2014
Q3 | $80K | Hold |
8,000
| – | – | 0.01% | 1192 |
|
|
2014
Q2 | $125K | Hold |
8,000
| – | – | 0.02% | 1004 |
|
|
2014
Q1 | $148K | Hold |
8,000
| – | – | 0.02% | 849 |
|
|
2013
Q4 | $153K | Hold |
8,000
| – | – | 0.03% | 693 |
|
|
2013
Q3 | $131K | Buy |
+8,000
| New | +$84.1K | 0.02% | 687 |
|
Other funds holding PETX
Prelude Capital Management's PETX Position: Q3 2019 in Review
Prelude Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 18,378 shares — an estimated $95K sold.
Prelude Capital Management first reported a position in PETX in Q3 2013 and held it in 18 quarters. The position peaked at $276K in Q3 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Prelude Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Prelude Capital Management sold 18,378 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $95K.
- Prelude Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 18 quarters.
- Prelude Capital Management's Aratana Therapeutics, Inc. position peaked at $276K in Q3 2015.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Prelude Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.